The decreased levels of Wnt3a and TGF-β1 in keloid tissue explants treated with dEl-k35/sLRP6E1E2 was reduced by 91% and 43%, respectively, in comparison to dE1-k35/LacZ-treated keloid tissue explants (Fig. 5a,b, and Supplementary Figure S2). This evidence concerns the gene WNT3A and keloid.